ECSP972193A - PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS - Google Patents
PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORSInfo
- Publication number
- ECSP972193A ECSP972193A ECSP972193A ECSP972193A EC SP972193 A ECSP972193 A EC SP972193A EC SP972193 A ECSP972193 A EC SP972193A EC SP972193 A ECSP972193 A EC SP972193A
- Authority
- EC
- Ecuador
- Prior art keywords
- tnf
- cancer
- matrix
- treatment
- production
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010039705 Scleritis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical class C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere a derivados basados en fosfinatos que son inhibidores de mataloproteinasas matriciales o de la producción de factor de necrosis tumoral (TNF) y que, como tales, son útiles en el tratamiento de una condición seleccionada del grupo formado por artritis, cáncer, ulceración de tejidos, restenosis, enfermedad peridontal epidermólisis ampollosas, escleritis, otras enfermedades caracterizadas por actividad de metloproteinasas matriciales, SIDA(Sindrome inmunodeficiencia adquirida), sepsis, shock séptico y otras enfermedades que implican la producción de TNF. Además los compuestos de la presente invención se pueden usar en terapia combinada con fármacos antinflamatorios no esteroides y analgésicos standar y combinados con fármacos citotóxicos como adriamicina, daunomicina, cisplatino, etopósido, taxol, taxotero y otros alcaloides con vincristina, en el tratamiento del cáncer.This invention relates to derivatives based on phosphinates that are inhibitors of matrix mataloproteinases or the production of tumor necrosis factor (TNF) and that, as such, are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, peridontal disease, epidermolysis bullosa, scleritis, other diseases characterized by activity of matrix metloproteinases, AIDS (acquired immunodeficiency syndrome), sepsis, septic shock, and other diseases that involve the production of TNF. Furthermore, the compounds of the present invention can be used in combination therapy with non-steroidal anti-inflammatory drugs and standard analgesics and combined with cytotoxic drugs such as adriamycin, daunomycin, cisplatin, etoposide, taxol, taxoter and other vincristine alkaloids, in the treatment of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP972193 ECSP972193A (en) | 1997-07-18 | 1997-07-18 | PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP972193 ECSP972193A (en) | 1997-07-18 | 1997-07-18 | PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP972193A true ECSP972193A (en) | 1998-09-22 |
Family
ID=42043024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP972193 ECSP972193A (en) | 1997-07-18 | 1997-07-18 | PHOSPHINATE BASED MATRIO METALOPROTEASE INHIBITORS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP972193A (en) |
-
1997
- 1997-07-18 EC ECSP972193 patent/ECSP972193A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4890852A1 (en) | MATRICIAL METALOPROTEASE INHIBITORS BASED ON PHOSPHYTES | |
| BR9714266A (en) | Cyclic sulfone derivatives. | |
| NO990821L (en) | Arylsulfonylamino-hydroxamic acid derivatives | |
| EA199900641A1 (en) | Derivatives of arylsulfonylhydroxamic acid | |
| GT199800025A (en) | ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES. | |
| AR069374A2 (en) | VALSARTAN SALTS, PROCESS FOR MANUFACTURING, PHARMACEUTICAL COMPOSITIONS AND USE OF SALES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE LOCK OF THE AT1 RECEIVER. | |
| BR0307796A (en) | Tricyclic Pyrazole Derivatives for the Treatment of Inflammation | |
| UY25992A1 (en) | PROCEDURE FOR PREPARING TACE INHIBITORS (TUMOR NECROSIS ALPHA FACTOR CONVERSING ENZYME) | |
| GT200100183A (en) | DERIVATIVES OF QUINOLINA AND QUINAZOLINA. | |
| ES2178724T3 (en) | ARILSULFONAMIDE ALPHA-SUBSTITUTED HYDROXAMIC ACIDS AS INHIBITORS OF ALFA TUMOR NECROSIS FACTOR AND MATRIX METALOPROTEINASES. | |
| CY1110067T1 (en) | INDOLINASE SUBSTITUTES IN SECTION 6, PRODUCING THESE AND USING THESE AS MEDICINES | |
| CY1106125T1 (en) | INDAZOLILU SUBSTITUTED PYRROLINE COMPOUNDS AS KINASE INHIBITORS | |
| BR0212611A (en) | Substituted pyrazolyl compounds for the treatment of inflammation | |
| WO2001074376A3 (en) | Cathepsin inhibitors in cancer treatment | |
| WO2005007099A3 (en) | Pkb inhibitors as anti-tumor agents | |
| ES2192877T3 (en) | 4-ALQUENIL (AND ALQUINIL) OXINDOLS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES, IN PARTICULAR CDK2. | |
| ECSP066458A (en) | 6 - [(REPLACED) PHENYL] TRIAZOLOPIRIMIDINAS AS ANTICANCER AGENTS | |
| ECSP099539A (en) | DERIVATIVES OF 3-CINOLINACARBOXAMIDE AND ITS USE TO TREAT CANCER | |
| ES2192878T3 (en) | 4,5-AZOLO-OXINDOLS. | |
| HN2000000074A (en) | HYDROXIAMIDES OF ACIDS 3- (ARILSULFONILAMINO) -TETRAHIDROPIRAN-3-CARBOXILICOS. | |
| ECSP982394A (en) | ARILSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES | |
| ECSP982358A (en) | CYCLE DERIVATIVES OF SULFONA | |
| ECSP972233A (en) | DERIVATIVES OF ACID ARILSULFONILAMINO HIDROXAMICO | |
| ATE406375T1 (en) | ANTITUMOR EFFECTIVE 2-SUBSTITUTED D-HOMOESTRA-1, 3,5(10)-TRIEN-3-YL SULFAMATES | |
| UY32230A (en) | DIFENILUREAS (OMEGA) - REPLACED CARBOXIARILICS AS INHIBITORS OF RAF-QUINASA |